Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report

This is the first case report of a 60-yr-old female who underwent therapy for metastatic pancreatic cancer with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Upon the progression of her disease, she was switched to gemcitabine and nab-paclitaxel. Per genomic sequencing, her tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardalan, Bach, Azqueta, Jose Ignacio, England, Jonathan, Eatz, Tiffany Alyssa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559623/
https://www.ncbi.nlm.nih.gov/pubmed/34667063
http://dx.doi.org/10.1101/mcs.a006108
_version_ 1784592794710441984
author Ardalan, Bach
Azqueta, Jose Ignacio
England, Jonathan
Eatz, Tiffany Alyssa
author_facet Ardalan, Bach
Azqueta, Jose Ignacio
England, Jonathan
Eatz, Tiffany Alyssa
author_sort Ardalan, Bach
collection PubMed
description This is the first case report of a 60-yr-old female who underwent therapy for metastatic pancreatic cancer with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Upon the progression of her disease, she was switched to gemcitabine and nab-paclitaxel. Per genomic sequencing, her tumor was found to be a KRAS wild-type and BRAF V600E mutation, which then warranted treatment with the MEK1 and MEK2 inhibitor, cobimetinib. The patient has achieved a complete response (CR) to a combination of gemcitabine, nab-paclitaxel, and cobimetinib. It has been 16 mo since the start of the treatment, and the patient continues to demonstrate a complete durable response both serologically and radiologically.
format Online
Article
Text
id pubmed-8559623
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cold Spring Harbor Laboratory Press
record_format MEDLINE/PubMed
spelling pubmed-85596232021-11-10 Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report Ardalan, Bach Azqueta, Jose Ignacio England, Jonathan Eatz, Tiffany Alyssa Cold Spring Harb Mol Case Stud Research Report This is the first case report of a 60-yr-old female who underwent therapy for metastatic pancreatic cancer with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Upon the progression of her disease, she was switched to gemcitabine and nab-paclitaxel. Per genomic sequencing, her tumor was found to be a KRAS wild-type and BRAF V600E mutation, which then warranted treatment with the MEK1 and MEK2 inhibitor, cobimetinib. The patient has achieved a complete response (CR) to a combination of gemcitabine, nab-paclitaxel, and cobimetinib. It has been 16 mo since the start of the treatment, and the patient continues to demonstrate a complete durable response both serologically and radiologically. Cold Spring Harbor Laboratory Press 2021-10 /pmc/articles/PMC8559623/ /pubmed/34667063 http://dx.doi.org/10.1101/mcs.a006108 Text en © 2021 Ardalan et al.; Published by Cold Spring Harbor Laboratory Press https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.
spellingShingle Research Report
Ardalan, Bach
Azqueta, Jose Ignacio
England, Jonathan
Eatz, Tiffany Alyssa
Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
title Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
title_full Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
title_fullStr Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
title_full_unstemmed Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
title_short Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
title_sort potential benefit of treatment with mek inhibitors and chemotherapy in braf-mutated kras wild-type pancreatic ductal adenocarcinoma patients: a case report
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559623/
https://www.ncbi.nlm.nih.gov/pubmed/34667063
http://dx.doi.org/10.1101/mcs.a006108
work_keys_str_mv AT ardalanbach potentialbenefitoftreatmentwithmekinhibitorsandchemotherapyinbrafmutatedkraswildtypepancreaticductaladenocarcinomapatientsacasereport
AT azquetajoseignacio potentialbenefitoftreatmentwithmekinhibitorsandchemotherapyinbrafmutatedkraswildtypepancreaticductaladenocarcinomapatientsacasereport
AT englandjonathan potentialbenefitoftreatmentwithmekinhibitorsandchemotherapyinbrafmutatedkraswildtypepancreaticductaladenocarcinomapatientsacasereport
AT eatztiffanyalyssa potentialbenefitoftreatmentwithmekinhibitorsandchemotherapyinbrafmutatedkraswildtypepancreaticductaladenocarcinomapatientsacasereport

Ejemplares similares